ENZ - יחס חוב להיוון בספרים Enzo Biochem

Enzo Biochem, Inc. (ENZ) generates revenue through diagnostic services and patent monetization. This chart from GURU.Markets illustrating the debt-to-market cap ratio confirms the liability trend, where the 0.07 mark indicates the level of debt load. The business is currently focusing on reagent production, while share price growth is supported by the licensing of molecular systems and asset restructuring.

Reliable defensive assets are characterized by low debt loads and high financial autonomy. Enzo Biochem, Inc. (ENZ) maintains resilience by monetizing an extensive patent portfolio in the field of DNA labeling. This metric compares total liabilities to the book value of equity, determining the business's degree of dependence on borrowed funds. By analyzing the current ratio of liabilities to book capitalization on GURU.Markets, an investor assesses the default risk. A decrease in this coefficient confirms the company's growing solvency.